May 19, 2020 / 12:22 PM / 6 days ago

BRIEF-Hepion's CRV431 Advances To Phase 2 Trial For Nash Fibrosis

May 19 (Reuters) - Hepion Pharmaceuticals Inc:

* HEPION PHARMACEUTICALS CRV431 FIRST CYCLOPHILIN INHIBITOR TO ADVANCE TO PHASE 2 TRIAL FOR NASH FIBROSIS

* HEPION PHARMACEUTICALS INC - RESULTS FROM HEPION'S PHASE 2A AMBITION STUDY EXPECTED BY YEAR-END 2020 Source text: (bit.ly/3g35HJD) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below